Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Imv Inc (IMV.TO)

Imv Inc (IMV.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 13,117
  • Shares Outstanding, K 11,712
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,991 K
  • 60-Month Beta 0.78
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade IMV.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -4.55
  • Most Recent Earnings $-0.95 on N/A
  • Next Earnings Date 06/09/23
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -1.47
  • Number of Estimates 1
  • High Estimate -1.47
  • Low Estimate -1.47
  • Prior Year -1.60
  • Growth Rate Est. (year over year) +8.13%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.68 +64.71%
on 03/29/23
1.36 -17.65%
on 04/25/23
+0.44 (+64.71%)
since 03/28/23
3-Month
0.62 +80.65%
on 03/27/23
3.35 -66.57%
on 02/06/23
-1.74 (-60.84%)
since 01/27/23
52-Week
0.62 +80.65%
on 03/27/23
15.90 -92.96%
on 05/02/22
-14.58 (-92.87%)
since 04/28/22

Most Recent Stories

More News
IMV Receives NASDAQ Delisting Notice

IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Initiates Restructuring Proceedings Under the CCAA to Complete the Review of its Strategic Alternatives

IMV Inc. (the “ Company ” or “ IMV ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX ® platform...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Changes to Its Board of Directors

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
Stocks in play: IMV Inc.

Announced positive preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, ...

IMV.TO : 1.12 (-1.75%)
IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)
IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX...

IMV.TO : 1.12 (-1.75%)
IMV : 0.8225 (-2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

IMV Inc is a clinical-stage biopharmaceutical company. The company is engaged in making immunotherapies more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. Its proprietary drug development platform provides a patented delivery formulation...

See More

Key Turning Points

3rd Resistance Point 1.20
2nd Resistance Point 1.17
1st Resistance Point 1.14
Last Price 1.12
1st Support Level 1.08
2nd Support Level 1.05
3rd Support Level 1.02

See More

52-Week High 15.90
Fibonacci 61.8% 10.06
Fibonacci 50% 8.26
Fibonacci 38.2% 6.46
Last Price 1.12
52-Week Low 0.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar